Synergistic anti-tumor effects of Liraglutide, a glucagon-like peptide-1 receptor agonist, along with Docetaxel on LNCaP prostate cancer cell line

Eftekhari, Sanaz; Montazeri, Hamed; Tarighi, Parastoo

doi:10.1016/j.ejphar.2020.173102

Cited by 20 publications

(11 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is well demonstrated that PI3K/AKT signaling pathway mediates the process of chemoresistance through multiple pathways, including expression of apoptosis-related proteins, ABC transport, NF-κB, mTOR signaling, etc [ 43 ]. In prostate cancer cell lines, inhibition of the MAPK/ERK pathway could contribute to the suppression of cell proliferation and promotes apoptosis, and sensitization to docetaxel treatment [ 44 ].…”

Section: Discussionmentioning

confidence: 99%

Identification of biomarkers, pathways and potential therapeutic target for docetaxel resistant prostate cancer

Liu

et al. 2021

Bioengineered

View full text Add to dashboard Cite

Docetaxel has been proved to provide survival benefit for advanced prostate cancer (PCa) patients. Resistance to docetaxel further reduces the survival of these patients. Herein, we performed a comprehensive bioinformatic analysis to identify differentially expressed genes (DEGs) between docetaxel sensitive and resistant PCa (DRPC) cell based on Gene Expression Omnibus (GEO) database. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were applied for functional and pathway analysis of DEGs. The STRING database, cytoscape software and plug-in 'cytoHubba' were used to construct protein-protein interaction (PPI) networks and identify hub genes. Survival analysis were performed via GEPIA database. Finally, we conducted immune infiltration analysis by TIMER. A total of 460 DEGs were identified. GO functional analysis showed that these DEGs are mainly enriched in chemotaxis, negative regulation of intracellular signal transduction, and regulation of cell adhesion, positive regulation of inflammatory response, regulation of response to cytokine stimulus. According to the results of KEGG pathway analysis, these DEGs are mainly involved in signaling by Rho GTPases, Miro GTPases and RHOBTB3; interferon Signaling; arginine biosynthesis; PI3K-Akt signaling pathway; cytokine-cytokine receptor interaction; MAPK signaling pathway. Finally, CCNB1 and EZH2 were identified as prognostic hub genes and the expression of these two genes were associated with immune infiltration. The present study may helps to improve the understanding of the molecular mechanisms of DRPC and facilitate the selection of therapeutic and prognostic biomarkers for DRPC.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of biomarkers, pathways and potential therapeutic target for docetaxel resistant prostate cancer

Liu

et al. 2021

Bioengineered

View full text Add to dashboard Cite

show abstract

“…Therefore, a combination of GLP-1RAs with anticancer drugs could indirectly inhibit the migration, invasion, and growth of tumors by increasing the chemosensitivity of cancer cells. Interestingly, this approach seems to be more effective for the treatment of patients with advanced cancer ( 210 , 215 ).…”

Section: Effects Of Glucagon Like Peptide-1 Receptor Agonists On Tumor Diseasesmentioning

confidence: 99%

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects

et al. 2021

View full text Add to dashboard Cite

Glucagon like peptide-1 (GLP-1) is an incretin secretory molecule. GLP-1 receptor agonists (GLP-1RAs) are widely used in the treatment of type 2 diabetes (T2DM) due to their attributes such as body weight loss, protection of islet β cells, promotion of islet β cell proliferation and minimal side effects. Studies have found that GLP-1R is widely distributed on pancreatic and other tissues and has multiple biological effects, such as reducing neuroinflammation, promoting nerve growth, improving heart function, suppressing appetite, delaying gastric emptying, regulating blood lipid metabolism and reducing fat deposition. Moreover, GLP-1RAs have neuroprotective, anti-infectious, cardiovascular protective, and metabolic regulatory effects, exhibiting good application prospects. Growing attention has been paid to the relationship between GLP-1RAs and tumorigenesis, development and prognosis in patient with T2DM. Here, we reviewed the therapeutic effects and possible mechanisms of action of GLP-1RAs in the nervous, cardiovascular, and endocrine systems and their correlation with metabolism, tumours and other diseases.

show abstract

“…Various experimental studies on animals, cancer cell lines, and clinical data have shown that GLP-1 receptor agonists of antidiabetic drugs have potential clinical benefits for breast cancer [106] , prostate cancer [107] , colorectal cancer [108] , [109] , ovarian cancer [110] , endometrial cancer [111] , pancreatic cancer [112] , [113] , and polycystic ovary syndrome [114] . SGLT-2 is one of the transporters for active glucose uptake in cancer cells.…”

Section: Repositioning Potential Of Antidiabetic Drugsmentioning

confidence: 99%

Drug repositioning in drug discovery of T2DM and repositioning potential of antidiabetic agents

Zhu

Bai

et al. 2022

Computational and Structural Biotechnology Journal

View full text Add to dashboard Cite

Synergistic anti-tumor effects of Liraglutide, a glucagon-like peptide-1 receptor agonist, along with Docetaxel on LNCaP prostate cancer cell line

Cited by 20 publications

References 30 publications

Identification of biomarkers, pathways and potential therapeutic target for docetaxel resistant prostate cancer

Identification of biomarkers, pathways and potential therapeutic target for docetaxel resistant prostate cancer

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects

Drug repositioning in drug discovery of T2DM and repositioning potential of antidiabetic agents

Contact Info

Product

Resources

About